Twist Bioscience Corp

The holders of shares of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors.

SEC original ↗Twist Bioscience Corp — 10-Q Quarterly report10-QAug 3, 2026

The Form S-3ASR replaced the Company s prior shelf registration statement and permits the Company to offer and sell, from time to time, common stock, preferred stock, debt securities, units and warrants in one or more offerings.

SEC original ↗Twist Bioscience Corp — 10-Q Quarterly report10-QAug 3, 2026

In the third quarter of fiscal 2025, we delivered another quarter of record revenue by focusing on delivering an exceptional customer experience, expanding our product portfolio, and deepening our reach into the long tail of the academic market across both synthetic biology and NGS, said Emily M.

SEC original ↗Twist Bioscience Corp — Earnings release (8-K exhibit)EX-99Aug 4, 2025

All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading Updated Fiscal 2025 Financial Guidance , statements regarding future growth and expansion, revenue and gross margin growth, estimated annual revenues, ability and timing to achieve profitability, ability and timing to achieve adjusted EBITDA breakeven and ability to increase gross margin, introduction of new products and newly announced partnerships.

SEC original ↗Twist Bioscience Corp — Earnings release (8-K exhibit)EX-99Aug 4, 2025

These statements relate to, among other matters, future growth, expansion and other expectations regarding future operations plans and financial performance.

SEC original ↗Twist Bioscience Corp — 10-Q Quarterly report10-QAug 3, 2026

Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

SEC original ↗Twist Bioscience Corp — Earnings release (8-K exhibit)EX-99Aug 4, 2025

For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist s business in general, see Twist s risk factors set forth in Twist s Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC.

SEC original ↗Twist Bioscience Corp — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Legal Proceedings 36 Item 1A.

SEC original ↗Twist Bioscience Corp — 10-Q Quarterly report10-QAug 3, 2026

Such statements are based on management s expectations as of the date of this filing and involve many risks and uncertainties that could cause our actual results, events or circumstances to differ materially from those expressed or implied in our forward-looking statements.

SEC original ↗Twist Bioscience Corp — 10-Q Quarterly report10-QAug 3, 2026

Beginning in the current period, the Company presents accrued expenses and other current liabilities on a combined basis in the condensed consolidated balance sheets, with the detailed components, including litigation accruals, disclosed in the accompanying footnotes; prior-period amounts have been reclassified to conform to the current presentation.

SEC original ↗Twist Bioscience Corp — 10-Q Quarterly report10-QAug 3, 2026

Commitments and Contingencies Legal Proceedings The Company may be subject to litigation, claims and disputes in the ordinary course of business.

SEC original ↗Twist Bioscience Corp — 10-Q Quarterly report10-QAug 3, 2026